Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell carcinoma of the lung, including the following cell types:~  * Adenocarcinoma~ * Large cell carcinoma~ * Squamous cell carcinoma~ * Mixture of these types~* A tissue block must be available at the time of registration~* Tumor expresses COX-2 (COX-2 index ≥ 2)~* Stage IIIB disease with malignant pleural effusion, supraclavicular node involvement, or contralateral hilar node involvement OR stage IV disease~  * Patients with stage IIIB disease who are eligible for clinical trials that involve combined chemotherapy and chest irradiation are not eligible for this study~* Patients with stage IV disease are eligible~* Patients with recurrent disease, not amenable to (or refusing) a potentially curative therapy, are eligible~* Measurable or non-measurable disease~  * Measurable disease is defined as lesions that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 2 cm with conventional techniques or as ≥ 1 cm with spiral CT scan~ * Non-measurable disease is defined as all other lesions, including small lesions (longest diameter \< 20 mm with conventional techniques or \< 10 mm with spiral CT scan) and truly nonmeasurable lesions, including any of the following:~    * Bone lesions~   * Leptomeningeal disease~   * Ascites~   * Pleural/pericardial effusion~   * Inflammatory breast disease~   * Lymphangitis cutis/pulmonis~   * Abdominal masses that are not confirmed and followed by imaging techniques~   * Cystic lesions~* Patients with symptomatic CNS metastases are eligible provided they received prior therapy (e.g., surgery, radiotherapy, or gamma knife), are neurologically stable, and are off steroids for ≥ 14 days before study entry~  * Patients with asymptomatic CNS metastases without associated edema, shift, or requirement for steroids or antiseizure medications may be eligible after discussion with the Study Chair~ * Patients should be off steroids at least 7 days before preregistration~* No leptomeningeal disease or carcinomatous meningitis~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Granulocytes ≥ 1,500/μL~* Platelet count ≥ 100,000/μL~* Creatinine clearance ≥ 45 mL/min~* Bilirubin ≤ 1.5 mg/dL~* AST and ALT ≤ 2.0 times upper limit of normal (ULN) (≤ 5.0 times ULN if liver metastases are present)~* Serum albumin ≥ 2.5 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* No currently active second malignancy other than non-melanoma skin cancer~  * Patients are not considered to have a currently active malignancy if they have completed therapy and are considered by their physician to be at \< 30% risk of relapse~* No known hypersensitivity to aspirin, NSAIDs, or sulfonamides~* No active ulcer disease~  * No history of gastrointestinal bleeding within the past three years~* None of the following cardiovascular conditions within the past 6 months:~  * Myocardial infarction~ * Unstable angina~ * Symptomatic congestive heart failure~ * Serious uncontrolled cardiac arrhythmia~ * Cerebrovascular accident or transient ischemic attack~ * Pulmonary embolism~ * Symptomatic carotid artery or peripheral vascular disease~ * Deep vein thrombosis~ * Other significant thromboembolic event~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy, immunotherapy, or other systemic therapy for non-small cell lung cancer, including adjuvant therapy~* At least 2 weeks since prior surgery and recovered~* At least 7 days since prior radiotherapy~* At least 14 days since prior NSAIDs (other than low-dose aspirin \[≤ 325 mg daily\]), including any of the following:~  * Celecoxib~ * Choline Mg~ * Trisalicylate (Trilisate®)~ * Ibuprofen (Advil® or Motrin®)~ * Naproxen (Aleve®, Naprosyn® or Anaprox®)~ * Etodolac (Lodine®)~ * Oxaprozin (Daypro®)~ * Diflunisal (Dolobid®)~ * Nabumetone (Relafen®)~ * Tolmetin (Tolectin®)~ * Valdecoxib (Bextra®)~* No chronic use of NSAIDs (i.e., \> 4 weeks of daily use)~  * Patients on low-dose aspirin are eligible~* No other concurrent chemotherapy or hormonal therapy (other than megestrol acetate \[Megace\] for appetite stimulation)~* No other concurrent investigational therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive gemcitabine hydrochloride\* IV on days 1 and 8 OR pemetrexed disodium\* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib twice daily on days 1-21.
- Arm II (Type: ACTIVE_COMPARATOR): Patients receive gemcitabine hydrochloride\* OR pemetrexed disodium\* and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues